首页> 外文期刊>The Biochemical Journal >Molecular cloning, expression and catalytic activity of a human AKR7 member of the aldo-keto reductase superfamily: evidence that the major 2-carboxybenzaldehyde reductase from human liver is a homologue of rat aflatoxin B-1 aldehyde reductase
【24h】

Molecular cloning, expression and catalytic activity of a human AKR7 member of the aldo-keto reductase superfamily: evidence that the major 2-carboxybenzaldehyde reductase from human liver is a homologue of rat aflatoxin B-1 aldehyde reductase

机译:醛糖酮还原酶超家族的人AKR7成员的分子克隆,表达和催化活性:证据表明人肝脏中主要的2-羧基苯甲醛还原酶是大鼠黄曲霉毒素B-1醛还原酶的同源物

获取原文
获取原文并翻译 | 示例
           

摘要

The masking of charged amino or carboxy groups by N-phthalidylation and O-phthalidylation has been used to improve the absorption of many drugs, including ampicillin and 5-fluorouracil. Following absorption of such prodrugs, the phthalidyl group is hydrolysed to release 2-carboxybenzaldehyde (2-CBA) and the pharmaceutically active compound; in humans, 2-CBA is further metabolized to 2-hydroxymethylbenzoic acid by reduction of the aldehyde group. In the present work, the enzyme responsible for the reduction of 2-CBA in humans is identified as a homologue of rat aflatoxin B-1-aldehyde reductase (rAFAR). This novel human aldo-keto reductase (AKR) has been cloned from a liver cDNA library, and together with the rat protein, establishes the AKR7 family of the AKR superfamily. Unlike its rat homologue, human AFAR (hAFAR) appears to be constitutively expressed in human liver, and is widely expressed in extrahepatic tissues. The deduced human and rat protein sequences share 78 % identity and 87 % similarity. Although the two AKR7 proteins are predicted to possess distinct secondary structural features which distinguish them from the prototypic AKR1 family of AKRs, the catalytic-and NADPH-binding residues appear to be conserved in both families. Certain of the predicted structural features of the AKR7 family members are shared with the AKR6 beta-subunits of voltage-gated K+-channels. In addition to reducing the dialdehydic form of aflatoxin B-1-8,9-dihydrodiol, hAFAR shows high affinity for the gamma-aminobutyric acid metabolite succinic semialdehyde (SSA) which is structurally related to 2-CBA, suggesting that hAFAR could function as both a SSA reductase and a 2-CBA reductase in vivo. This hypothesis is supported in part by the finding that the major peak of 2-CBA reductase activity in human liver co-purifies with hAFAR protein. [References: 66]
机译:通过N-邻苯二甲酰化和O-邻苯二甲酰化对带电荷的氨基或羧基进行掩蔽已被用于改善许多药物的吸收,包括氨苄青霉素和5-氟尿嘧啶。吸收这些前药后,将萘基水解以释放出2-羧基苯甲醛(2-CBA)和药物活性化合物。在人类中,2-CBA通过醛基的还原进一步代谢为2-羟甲基苯甲酸。在当前的工作中,负责减少人类2-CBA的酶被鉴定为大鼠黄曲霉毒素B-1-醛还原酶(rAFAR)的同源物。该新的人类醛酮还原酶(AKR)已从肝脏cDNA文库中克隆出来,并与大鼠蛋白质一起建立了AKR超家族的AKR7家族。与它的大鼠同源物不同,人AFAR(hAFAR)似乎在人肝中组成性表达,并在肝外组织中广泛表达。推导的人和大鼠蛋白质序列具有78%的同一性和87%的相似性。尽管预测这两种AKR7蛋白具有与原型AKRs AKRs家族区分开的独特二级结构特征,但催化和NADPH结合残基在这两个家族中均保守。 AKR7家族成员的某些预测的结构特征与电压门控K +通道的AKR6β亚基共有。除减少黄曲霉毒素B-1-8,9-二氢二醇的二醛形式外,hAFAR还对与2-CBA结构相关的γ-氨基丁酸代谢物琥珀酸半醛(SSA)具有高亲和力,这表明hAFAR可以作为体内SSA还原酶和2-CBA还原酶均如此。这一假设部分得到以下发现的支持:人类肝脏中2-CBA还原酶活性的主要峰与hAFAR蛋白共同纯化。 [参考:66]

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号